Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab added to rosuvastatin versus ezetimibe add-on versus rosuvastatin dose increase in uncontrolled hypercholesterolemia
2012-002333-11Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia and familial hypercholesterolemia (FH) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change in calculated LDL-C from baseline to week 24. Started Nov 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2012-002333-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002333-11.